ArticleBMC complementary medicine and therapies2026
Effects of nanosilymarin and conditioned medium of adipose-derived mesenchymal stem cells on peripheral blood mononuclear cells co-cultured with HeLa cells.
Article in BMC complementary medicine and therapies, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCervical cancer is the fourth most common malignancy in females worldwide. Silymarin, a flavonoid with established anti-inflammatory properties, shows promise in oncology. Conditioned medium (CM) of Mesenchymal stem cell (MSC) exerts paracrine immunomodulatory effects. This study evaluated the combined impact of CM of adipose tissue-derived MSC (AD-MSC) and nanosilymarin on peripheral blood mononuclear cells (PBMC) from healthy donors co-cultured with HeLa cervical cancer cells.
methodsAD-MSCs were isolated from adipose tissue via collagenase I digestion, characterized by immunophenotyping and multilineage differentiation potential. Apoptosis (Annexin V/PI), proliferation (MTT assay), and gene expression of IFN-γ, TNF-α, IL-4, and TGF-β (qRT-PCR) were assessed in PBMC treated with AD-MSC-CM (50%) and/or nanosilymarin (25 µM) for 48 h, in monoculture or HeLa co-culture.
resultsIn PBMC-HeLa co-culture, nanosilymarin (different concentrations) with 50% MSC-CM significantly reduced PBMC proliferation. Nanosilymarin (25 µM) plus MSC-CM induced marked HeLa apoptosis. Both agents together upregulated IFN-γ expression in PBMC, in monoculture and co-culture, without altering TNF-α, IL-4, or TGF-β.
conclusionNanosilymarin combined with AD-MSC-CM enhances PBMC-mediated anti-tumor immunity via IFN-γ upregulation and promotes HeLa apoptosis, suggesting synergistic potential for cervical cancer immunotherapy. Mechanistic studies and dose optimization are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.